Company intelligence / Profile preview

Tera Group

Ownership: Private
Development stage: Other

Overview

Tera Group develops terahertz wave–based diagnostic platforms capable of real-time, non-invasive detection of organic compounds and disease biomarkers from human breath. Their flagship product line includes the TeraBioStation system for rapid mass screening of infectious diseases such as COVID‑19. Clinical trials have demonstrated high sensitivity among pre-symptomatic/asymptomatic populations. The system has regulatory clearance or use cases across Israel, Latin America, Asia, UAE, Europe (CE Mark), with US FDA approval pending.

Therapeutic areas: Infectious DiseasesOther
Modalities: Device
Industry: Metabolite Diagnostics

Partnerships

Not explicitly listed. Regulatory approvals suggest collaborations/trials across Israel, Latin America, Asia, USA/UAE/EU.

Beyond the preview

Go deeper on Tera Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tera Group.

Explore the full profile